The estimated Net Worth of Mark B Logan is at least $9.14 Tausend dollars as of 8 November 2012. Mark Logan owns over 3,600 units of VIVUS stock worth over $9,143 and over the last 21 years Mark sold VVUS stock worth over $0.
Sign up
Mark Logan VVUS stock SEC Form 4 insiders trading
Mark has made over 4 trades of the VIVUS stock since 2012, according to the Form 4 filled with the SEC. Most recently Mark bought 3,600 units of VVUS stock worth $18,792 on 8 November 2012.
The largest trade Mark's ever made was exercising 49,816 units of VIVUS stock on 14 August 2012 worth over $280,962. On average, Mark trades about 2,378 units every 7 days since 2004. As of 8 November 2012 Mark still owns at least 19,600 units of VIVUS stock.
You can see the complete history of Mark Logan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Mark Logan's mailing address?
Mark's mailing address filed with the SEC is , , , , .
Insiders trading at VIVUS
Over the last 21 years, insiders at VIVUS have traded over $6,261,269 worth of VIVUS stock and bought 5,180,746 units worth $13,074,554 . The most active insiders traders include Tide Capital, Llc North Tid..., Alexander J Denner und Ernest Mario. On average, VIVUS executives and independent directors trade stock every 39 days with the average trade being worth of $35,394. The most recent stock trade was executed by John P. Amos on 1 March 2019, trading 11,000 units of VVUS stock currently worth $53,350.
What does VIVUS do?
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.
What does VIVUS's logo look like?
Complete history of Mark Logan stock trades at Staar Surgical Co und VIVUS
VIVUS executives and stock owners
VIVUS executives and other stock owners filed with the SEC include:
-
John Amos,
Chief Executive Officer, Director -
John Slebir,
Senior Vice President - Business Development, General Counsel, Secretary -
Santosh Varghese,
Senior Vice President, Chief Medical Officer -
Mark Oki,
Chief Financial Officer, Senior Vice President, Chief Accounting Officer -
Thomas King,
Independent Director -
David Norton,
Independent Chairman of the Board -
Jill Frizzley,
Independent Director -
Herman Rosenman,
Independent Director -
Jorge Plutzky,
Independent Director -
Edward Kangas,
Independent Director -
Karen Ferrell,
Independent Director -
Allan Shaw,
Director -
Herm Rosenman,
Director -
Eric W Roberts,
Director -
Tide Capital, Llc North Tid...,
-
Seth H. Z. Fischer,
Chief Executive Officer -
Mayu Sris,
Director -
Kenneth Suh,
President -
Wesley Day,
Vice President, Clinical -
Michael /Ny/ Miller,
Chief Commercial Officer -
Wang Changjin,
VP, Business Development -
Virgil A Place,
Chairman & CSO -
Graham Strachan,
Director -
Samuel F Colin,
Director -
Ernest Mario,
Director -
Anthony P. Zook,
Chief Executive Officer -
John W Dietrich,
Vice President, R & D -
Terry Nida,
VP, Worldwide Marketing/ -
Svai S Sanford,
Interim CFO -
Mario M Rosati,
Director -
Alexander J Denner,
Director -
Jon C Biro,
10% owner -
J Martin Carroll,
Director -
Robert N Wilson,
Director -
Alexander J Sarissa Capital...,
-
M. Scott Oehrlein,
Chief Operations Officer -
Timothy E Morris,
VP, Finance and CFO -
Leland F Wilson,
President & CEO -
Linda M Dairiki Shortliffe,
Director -
Charles J Casamento,
Director -
Lee Perry,
Vice President & Chief -
Jacob Pieter Kastelein Joha...,
Director -
Michael J Astrue,
Director -
Mark B Logan,
Director -
Michael Patrick Miller,
SVP, Chief Commercial Officer -
Guy P Marsh,
VP, Operations & General Mgr. -
Neil Gesundheit,
VP, Chief Medical Officer -
Larry J Strauss,
Vice President, Finance & CFO -
James R Nickel,
Vice President, Clinical -
Peter Y Tam,
VP, Business Planning -
Carol Zoltowski,
Vice President, Regulatory -
Lori Forrest,
VP, Operations & General Mgr.